155 related articles for article (PubMed ID: 37795066)
1. Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study.
Erande S; Mukhopadhyay J; Dange A; Deogaonkar A; Birla A; Doshi C; Revankar S; B SS; Kumar N; Kadam PV
Cureus; 2023 Sep; 15(9):e44548. PubMed ID: 37795066
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
Perez A; Zhao Z; Jacks R; Spanheimer R
Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
Khaladkar K; Mohan B; Khaladkar K; Suryawanshi S; Barkatestrong/Strong H
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443373
[TBL] [Abstract][Full Text] [Related]
4. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial.
Aashish M; Arindam N; Siddiqi SS; Bhosle D; Mallikarjuna VJ; Amol D; Sanket S; Omkar G; Parth P; Dhruvi H; Durga P; Pradeep D; Suresh K; Vaishali P; Mayura C; Indraneel B; Jayashri S; Arif F; Raghavendra SK; Deepak V; Ravindra T; Shaishav B; Vijay G; Khan K; Mahajani VV; Sharma AD; Mayabhate M; Pawar RR; Aiwale AS; Vinayaka S
Clin Diabetes Endocrinol; 2024 Feb; 10(1):3. PubMed ID: 38336931
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin.
Jain A; Vispute A; Dange A; Naskar A; Mondal A; Vivekanand B; Sharma B; Varade D; Shukla D; Bhatia G; Chaudhari H; Ram Babu K; Gavali O; Sorate S; Bhanushali S; Kothari V; Khandelwal V; Sharma A; Pawar R; Mayabhate M; Shahavi V; Rajput A; Jaiswal M
Diabetes Ther; 2024 Jan; 15(1):215-227. PubMed ID: 37957465
[TBL] [Abstract][Full Text] [Related]
9. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Bolli G; Dotta F; Rochotte E; Cohen SE
Diabetes Obes Metab; 2008 Jan; 10(1):82-90. PubMed ID: 18034842
[TBL] [Abstract][Full Text] [Related]
12. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
13. Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin.
Al Omari M; Khader Y; Dauod AS; Beni Yonis OA; Khassawneh AH
J Drug Assess; 2016; 5(1):29-33. PubMed ID: 27994943
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of vildagliptin/pioglitazone combination therapy in Korean patients with diabetes.
Kim SW; Baik SH; Yoon KH; Lee HW; Filozof C
World J Diabetes; 2010 Nov; 1(5):153-60. PubMed ID: 21537443
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus.
Ved P; Shah S
Indian J Endocrinol Metab; 2012 Mar; 16 Suppl 1(Suppl1):S110-3. PubMed ID: 22701828
[TBL] [Abstract][Full Text] [Related]
16. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.
Rosenstock J; Kim SW; Baron MA; Camisasca RP; Cressier F; Couturier A; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):175-85. PubMed ID: 17300593
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
Kim HJ; Jeong IK; Hur KY; Kim SK; Noh JH; Chun SW; Kang ES; Rhee EJ; Choi SH
Diabetes Metab J; 2022 Sep; 46(5):689-700. PubMed ID: 35295073
[TBL] [Abstract][Full Text] [Related]
20. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes.
Kozlovski P; Foley J; Shao Q; Lukashevich V; Kothny W
World J Diabetes; 2013 Aug; 4(4):151-6. PubMed ID: 23961326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
